Fineline Cube

Follow:
14486 Articles
China's CDE Announces 95th Batch of Reference Preparations for Public Comment
Policy / Regulatory

China’s CDE Announces 95th Batch of Reference Preparations for Public Comment

China Ministry of Finance Restricts EU-Imported Medical Devices in Government Procurement Over RMB45 Million
Policy / Regulatory

China Ministry of Finance Restricts EU-Imported Medical Devices in Government Procurement Over RMB45 Million

SCG Cell Therapy Obtains NMPA Approval for SCG101V in Chronic HBV Study
CompanyDrug

SCG Cell Therapy Obtains NMPA Approval for SCG101V in Chronic HBV Study

BGI Genomics Launches Mini Breast Cancer 76-Gene Detection System for Personalized Treatment
CompanyMedical Device

BGI Genomics Launches Mini Breast Cancer 76-Gene Detection System for Personalized Treatment

AstraZeneca's Imfinzi Approved in EU for Perioperative Treatment of Muscle-Invasive Bladder Cancer
CompanyDrug

AstraZeneca’s Imfinzi Approved in EU for Perioperative Treatment of Muscle-Invasive Bladder Cancer

Modella AI Collaborates with AstraZeneca to Accelerate Oncology Drug Development with AI
CompanyDeals

Modella AI Collaborates with AstraZeneca to Accelerate Oncology Drug Development with AI

CStone Pharmaceuticals Announces Phase III Trial Progress for Nofazinlimab in Hepatocellular Carcinoma
CompanyDrug

CStone Pharmaceuticals Announces Phase III Trial Progress for Nofazinlimab in Hepatocellular Carcinoma

Micot Raises Over RMB 100 Million in Series D Funding Led by Zheshang Venture Capital
CompanyDeals

Micot Raises Over RMB 100 Million in Series D Funding Led by Zheshang Venture Capital

NMPA Unveils Measures to Support High-End Medical Device Innovation with Full Lifecycle Regulation
Policy / Regulatory

NMPA Unveils Measures to Support High-End Medical Device Innovation with Full Lifecycle Regulation

AstraZeneca in Talks for $15B Licensing Deal for Ivonescimab with Summit Therapeutics
CompanyDeals

AstraZeneca in Talks for $15B Licensing Deal for Ivonescimab with Summit Therapeutics

Jiangsu Vcare PharmaTech's VC004 NDA Accepted for Review by China's NMPA
CompanyDrug

Jiangsu Vcare PharmaTech’s VC004 NDA Accepted for Review by China’s NMPA

Novartis' Cosentyx Fails to Meet Primary Endpoint in GCAptAIN Study for Giant Cell Arteritis
CompanyDrug

Novartis’ Cosentyx Fails to Meet Primary Endpoint in GCAptAIN Study for Giant Cell Arteritis